Hormonal contraception and HPV: a tale of differing and overlapping mechanisms

References

• Kamangar F, Dores GM, Anderson WF. Patterns of cancer incidence, mortality, and prevalence across five continents: defining priorities to reduce cancer disparities in different geographic regions of the world. J Clin Oncol. 2006;24(14):2137–2150.
   PubMed Web of Science ®Google Scholar
• Schiffman M, Castle PE, Jeronimo J, Rodriguez AC, Wacholder S. Human papillomavirus and cervical cancer. Lancet. 2007;370(9590):890–907.
   PubMed Web of Science ®Google Scholar
• Munoz N, Castellsague X, de Gonzalez AB, Gissmann L. Chapter 1: HPV in the etiology of human cancer. Vaccine. 2006;24S3:S1-S10.
   Google Scholar
• Moscicki AB, Schiffman M, Kjaer S, Villa LL. Chapter 5: Updating the natural history of HPV and anogenital cancer. Vaccine. 2006;24 Suppl 3: S3/42–51.
   Google Scholar
• Moreno V Bosch FX, Munoz N, et al. Effect of oral contraceptives on risk of cervical cancer in women with human papillomavirus infection: the IARC multicentric case-control study. Lancet. 2002;359(9312):1085–1092.
   PubMed Web of Science ®Google Scholar
• Appleby P, Beral V Berrington de Gonzalez A, et al. Cervical cancer and hormonal contraceptives: collaborative reanalysis of individual data for 16,573 women with cervical cancer and 35,509 women without cervical cancer from 24 epidemiological studies. Lancet. 2007;370(9599):1609–1621.
   PubMed Web of Science ®Google Scholar
• Smith J, Green J, de Gonzalez A, et al. Cervical Cancer and use of hormonal contraceptives: a systemic review. Lancet. 2003;361:1159–1167.
   PubMed Web of Science ®Google Scholar
• Cancer ICoESoC. Comparison of risk factors for invasive squamous cell carcinoma and adenocarcinoma of the cervix: collaborative reanalysis of individual data on 8,097 women with squamous cell carcinoma and 1,374 women with adenocarcinoma from 12 epidemiological studies. Int J Cancer. 2007;120(4):885–891.
   Web of Science ®Google Scholar
• Siegel DM, Klein DI, Roghmann KJ. Sexual behavior, contraception, and risk among college students. J Adolesc Health. 1999;25(5):336–343.
   PubMed Web of Science ®Google Scholar
• Blanc AK, Way AA. Sexual behavior and contraceptive knowledge and use among adolescents in developing countries. Stud Fam Plann. 1998;29(2):106–116.
   PubMed Web of Science ®Google Scholar
• Jacobson DL, Peralta L, Graham NM, Zenilman J. Histologic development of cervical ectopy: relationship to reproductive hormones. Sex Transm Dis. 2000;27(5):252–258.
   Web of Science ®Google Scholar
• Critchlow CW, Wolner-Hanssen P, Eschenbach DA, et al. Determinants of cervical ectopia and of cervicitis: age, oral contraception, specific cervical infection, smoking, and douching. Am J Obstet Gynecol. 1995;173(2):534–543.
   PubMed Web of Science ®Google Scholar
• Harrison HR, Costin M, Meder JB, et al. Cervical Chlamydia trachomatis infection in university women: relationship to history, contraception, ectopy, and cervicitis. Am J Obstet Gynecol. 1985;153(3):244–251.
   PubMed Web of Science ®Google Scholar
• Goldacre MJ, Loudon N, Watt B, et al. Epidemiology and clinical significance of cervical erosion in women attending a family planning clinic. Br Med J. 1978;1(6115):748–750.
   Google Scholar
• Roberts JN, Buck CB, Thompson CD, et al. Genital transmission of HPV in a mouse model is potentiated by nonoxynol-9 and inhibited by carrageenan. Nat Med. 2007;13(7):857–861.
   PubMed Web of Science ®Google Scholar
• Roberts JN, Kines RC, Katki HA, Lowy DR, Schiller JT. Effect of pap smear collection and carrageenan on cervicovaginal human papillomavirus-16 infection in a rhesus macaque model. J Natl Cancer Inst. 2011;103(9):737–743.
   PubMedGoogle Scholar
• Mauck CK, Callahan MM, Baker J, et al. The effect of one injection of Depo-Provera on the human vaginal epithelium and cervical ectopy. Contraception. 1999;60(1):15–24.
   Web of Science ®Google Scholar
• Kuhn L, Denny L, Pollack AE, Wright TC. Prevalence of visible disruption of cervical epithelium and cervical ectopy in African women using Depo-Provera. Contraception. 1999;59(6):363–367.
   Web of Science ®Google Scholar
• Green J, Berrington de Gonzalez A, Smith JS, et al. Human papillomavirus infection and use of oral contraceptives. Br J Cancer. 2003;88(11):1713–1720.
   Web of Science ®Google Scholar
• Burk RD, Ho GY, Beardsley L, Lempa M, Peters M, Bierman R. Sexual behavior and partner characteristics are the predominant risk factors for genital human papillomavirus infection in young women. J Infect Dis. 1996;174(4):679–689.
   PubMed Web of Science ®Google Scholar
• Kjaer SK, van den Brule AJ, Bock JE, et al. Determinants for genital human papillomavirus (HPV) infection in 1000 randomly chosen young Danish women with normal Pap smear: are there different risk profiles for oncogenic and nononcogenic HPV types? Cancer Epidemiol Biomarkers Prev. 1997;6(10):799–805.
   Web of Science ®Google Scholar
• Ley C, Bauer HM, Reingold A, et al. Determinants of genital human papillomavirus infection in young women. J Natl Cancer Inst. 1991 ;83(14):997–1003.
   PubMedGoogle Scholar
• Marks M, Gravitt PE, Gupta SB, et al. The association of hormonal contraceptive use and HPV prevalence. Int J Cancer. 2011;128(12):2962–2970.
   Web of Science ®Google Scholar
• Kotloff KL, Wasserman SS, Russ K, et al. Detection of genital human papillomavirus and associated cytological abnormalities among college women. Sex Transm Dis. 1998;25(5):243–250.
   Web of Science ®Google Scholar
• Pham TH, Nguyen TH, Herrero R, et al. Human papillomavirus infection among women in South and North Vietnam. Int J Cancer. 2003;104(2):213–220.
   PubMed Web of Science ®Google Scholar
• Rousseau MC, Franco EL, Villa LL, et al. A cumulative case-control study of risk factor profiles for oncogenic and nononcogenic cervical human papillomavirus infections. Cancer Epidemiol Biomarkers Prev. 2000;9(5):469–476.
   Web of Science ®Google Scholar
• Vaccarella S, Herrero R, Dai M, et al. Reproductive factors, oral contraceptive use, and human papillomavirus infection: pooled analysis of the IARC HPV prevalence surveys. Cancer Epidemiol Biomarkers Prev. 2006;15(11):2148–2153.
   PubMed Web of Science ®Google Scholar
• Molano M, Posso H, Weiderpass E, et al. Prevalence and determinants of HPV infection among Colombian women with normal cytology. Br J Cancer. 2002;87(3):324–333.
   Web of Science ®Google Scholar
• Harris TG, Miller L, Kulasingam SL, et al. Depot-medroxyprogesterone acetate and combined oral contraceptive use and cervical neoplasia among women with oncogenic human papillomavirus infection. Am J Obstet Gynecol. 2009;200(5):489 e1-e8.
   Web of Science ®Google Scholar
• Giuliano AR, Papenfuss M, Abrahamsen M, et al. Human papillomavirus infection at the United States-Mexico border: implications for cervical cancer prevention and control. Cancer Epidemiol Biomarkers Prev. 2001;10(11):1129–1136.
   PubMed Web of Science ®Google Scholar
• Monroy OL, Aguilar C, Lizano M, Cruz-Talonia F, Cruz RM, Rocha- Zavaleta L. Prevalence of human papillomavirus genotypes, and mucosal IgA anti-viral responses in women with cervical ectopy. J Clin Virol. 2010;47(1):43–48.
   Web of Science ®Google Scholar
• Rocha-Zavaleta L, Yescas G, Cruz RM, Cruz-Talonia F. Human papillomavirus infection and cervical ectopy. Int J Gynaecol Obstet. 2004;85(3):259–266.
   Web of Science ®Google Scholar
• Veress G, Csiky-Meszaros T, Czegledy J, Gergely L. Oral contraceptive use and human papillomavirus infection in women without abnormal cytological results. Med Microbiol Immunol. 1992;181(4):181–189.
   Web of Science ®Google Scholar
• Nielsen A, Iftner T, Monk C, Kjaer S. Acquisition of High-Risk Human Papillomavirus Infection in a Population-Based Cohort of Danish Women. Sex Transm Dis. 2009;36(10):609–615.
   Web of Science ®Google Scholar
• Winer RL, Lee SK, Hughes JP, Adam DE, Kiviat NB, Koutsky LA. Genital human papillomavirus infection: incidence and risk factors in a cohort of female university students. Am J Epidemiol. 2003;157(3):218–226.
   PubMed Web of Science ®Google Scholar
• Moscicki AB, Hills N, Shiboski S, Powell K, Jay N, Hanson E, et al. Risks for incident human papillomavirus infection and low-grade squamous intraepithelial lesion development in young females. JAMA. 2001;285(23):2995–3002.
   PubMed Web of Science ®Google Scholar
• Sellors JW, Karwalajtys TL, Kaczorowski J, et al. Incidence, clearance and predictors of human papillomavirus infection in women. CMAJ. 2003;168(4):421–425.
   Web of Science ®Google Scholar
• Morrison CS, Richardson BA, Mmiro F, et al. Hormonal contraception and the risk of HIV acquisition. Aids. 2007;21:85–95.
   PubMed Web of Science ®Google Scholar
• Marks M, Gravitt P, Gupta S, et al. Combined oral contraceptive use increases HPV persistence but not new HPV detection in a cohort of women from Thailand. J Infect Dis. 2011. In press.
   Web of Science ®Google Scholar
• Schlecht NF, Kulaga S, Robitaille J, et al. Persistent human papillomavirus infection as a predictor of cervical intraepithelial neoplasia. JAMA. 2001;286(24):3106–3114.
   Web of Science ®Google Scholar
• Ho GY, Burk RD, Klein S, et al. Persistent genital human papillomavirus infection as a risk factor for persistent cervical dysplasia. J Natl Cancer Inst. 1995;87(18):1365–1371.
   PubMed Web of Science ®Google Scholar
• Stanley M. Immune responses to human papillomavirus. Vaccine. 2006;24(Suppl 1):S16–S22.
   PubMed Web of Science ®Google Scholar
• Scott ME, Ma Y, Kuzmich L, Moscicki AB. Diminished IFN-gamma and IL-10 and elevated Foxp3 mRNA expression in the cervix are associated with CIN 2 or 3. Int J Cancer. 2009;124(6):1379–1383.
   Web of Science ®Google Scholar
• Garcia-Pineres AJ, Hildesheim A, Herrero R, et al. Persistent human papillomavirus infection is associated with a generalized decrease in immune responsiveness in older women. Cancer Res. 2006;66(22):11070–11076.
   PubMed Web of Science ®Google Scholar
• Bouman A, Heineman MJ, Faas MM. Sex hormones and the immune response in humans. Hum Reprod Update. 2005;11(4):411–423.
   PubMed Web of Science ®Google Scholar
• Straub RH. The complex role of estrogens in inflammation. Endocr Rev. 2007;28(5):521–574.
   PubMed Web of Science ®Google Scholar
• Kaushic C, Ashkar AA, Reid LA, Rosenthal KL. Progesterone increases susceptibility and decreases immune responses to genital herpes infection. J Virol. 2003;77(8):4558–4565.
   PubMed Web of Science ®Google Scholar
• Kaushic C, Zhou F, Murdin AD, Wira CR. Effects of estradiol and progesterone on susceptibility and early immune responses to Chlamydia trachomatis infection in the female reproductive tract. Infect Immun. 2000;68(7):4207–4216.
   PubMed Web of Science ®Google Scholar
• Fish EN. The X-files in immunity: sex-based differences predispose immune responses. Nat Rev Immunol. 2008;8(9):737–744.
   PubMed Web of Science ®Google Scholar
• Whitacre CC. Sex differences in autoimmune disease. Nat Immunol. 2001;2(9):777–780.
   PubMed Web of Science ®Google Scholar
• Kutteh WH, Franklin RD. Quantification of immunoglobulins and cytokines in human cervical mucus during each trimester of pregnancy. Am J Obstet Gynecol. 2001;184(5):865–872; discussion 72–74.
   Web of Science ®Google Scholar
• Piccinni MP T-cell cytokines in pregnancy. Am J Reprod Immunol. 2002;47(5):289–294.
   Web of Science ®Google Scholar
• Pacifici R, Brown C, Puscheck E, et al. Effect of surgical menopause and estrogen replacement on cytokine release from human blood mononuclear cells. Proc Natl Acad Sci U S A. 1991;88(12):5134–5138.
   PubMed Web of Science ®Google Scholar
• Puder JJ, Freda PU, Goland RS, Wardlaw SL. Estrogen modulates the hypothalamic-pituitary-adrenal and inflammatory cytokine responses to endotoxin in women. J Clin Endocrinol Metab. 2001 ;86(6):2403–2408.
   Web of Science ®Google Scholar
• Kamada M, Irahara M, Maegawa M, et al. Transient increase in the levels of T-helper 1 cytokines in postmenopausal women and the effects of hormone replacement therapy. Gynecol Obstet Invest. 2001;52(2):82–88.
   Web of Science ®Google Scholar
• Agarwal SK, Marshall GD Jr. Perimenstrual alterations in type- 1/type-2 cytokine balance of normal women. Ann Allergy Asthma Immunol. 1999;83(3):222–228.
   Web of Science ®Google Scholar
• Berg G, Ekerfelt C, Hammar M, Lindgren R, Matthiesen L, Ernerudh J. Cytokine changes in postmenopausal women treated with estrogens: a placebo-controlled study. Am J Reprod Immunol. 2002;48(2):63–69.
   Web of Science ®Google Scholar
• Yovel G, Shakhar K, Ben-Eliyahu S. The effects of sex, menstrual cycle, and oral contraceptives on the number and activity of natural killer cells. Gynecol Oncol. 2001;81(2):254–262.
   Web of Science ®Google Scholar
• Scanlan JM, Werner JJ, Legg RL, Laudenslager ML. Natural killer cell activity is reduced in association with oral contraceptive use. Psychoneuroendocrinology. 1995;20(3):281–287.
   Web of Science ®Google Scholar
• Rogers A, Eastell R. Effects of estrogen therapy of postmenopausal women on cytokines measured in peripheral blood. J Bone Miner Res. 1998;13(10):1577–1586.
   Web of Science ®Google Scholar
• Franklin RD, Kutteh WH. Characterization of immunoglobulins and cytokines in human cervical mucus: influence of exogenous and endogenous hormones. J Reprod Immunol. 1999;42(2):93–106.
   PubMed Web of Science ®Google Scholar
• Loy RA, Loukides JA, Polan ML. Ovarian steroids modulate human monocyte tumor necrosis factor alpha messenger ribonucleic acid levels in cultured human peripheral monocytes. Fertil Steril. 1992;58(4):733–739.
   Web of Science ®Google Scholar
• Ralston SH, Russell RG, Gowen M. Estrogen inhibits release of tumor necrosis factor from peripheral blood mononuclear cells in postmenopausal women. J Bone Miner Res. 1990;5(9):983–988.
   Web of Science ®Google Scholar
• Asai K, Hiki N, Mimura Y, Ogawa T, Unou K, Kaminishi M. Gender differences in cytokine secretion by human peripheral blood mononuclear cells: role of estrogen in modulating LPS-induced cytokine secretion in an ex vivo septic model. Shock. 2001;16(5):340–343.
   PubMed Web of Science ®Google Scholar
• Morishita M, Miyagi M, Iwamoto Y. Effects of sex hormones on production of interleukin-1 by human peripheral monocytes. J Periodontol. 1999;70(7):757–760.
   Web of Science ®Google Scholar
• Polan ML, Daniele A, Kuo A. Gonadal steroids modulate human monocyte interleukin-1 (IL-1) activity. Fertil Steril. 1988;49(6):964–968.
   Web of Science ®Google Scholar
• Polan ML, Loukides J, Nelson P, et al. Progesterone and estradiol modulate interleukin-1 beta messenger ribonucleic acid levels in cultured human peripheral monocytes. J Clin Endocrinol Metab. 1989;69(6):1200–1206.
   Web of Science ®Google Scholar
• Kanda N, Tsuchida T, Tamaki K. Estrogen enhancement of anti-double-stranded DNA antibody and immunoglobulin G production in peripheral blood mononuclear cells from patients with systemic lupus erythematosus. Arthritis Rheum. 1999;42(2):328–337.
   Google Scholar
• Kanda N, Tamaki K. Estrogen enhances immunoglobulin production by human PBMCs. J Allergy Clin Immunol. 1999;103(2 Pt 1):282–288.
   PubMed Web of Science ®Google Scholar
• Pauklin S, Sernandez IV, Bachmann G, Ramiro AR, Petersen-Mahrt SK. Estrogen directly activates AID transcription and function. J Exp Med. 2009;206(1):99–111.
   PubMed Web of Science ®Google Scholar
• Matalka KZ, Ali DA. Stress-induced versus preovulatory and pregnancy hormonal levels in modulating cytokine production following whole blood stimulation. Neuroimmunomodulation. 2005;12(6):366–374.
   Web of Science ®Google Scholar
• Prieto GA, Rosenstein Y. Oestradiol potentiates the suppressive function of human CD4 CD25 regulatory T cells by promoting their proliferation. Immunology. 2006;118(1):58–65.
   PubMed Web of Science ®Google Scholar
• Karpuzoglu E, Fenaux JB, Phillips RA, Lengi AJ, Elvinger F, Ansar Ahmed S. Estrogen up-regulates inducible nitric oxide synthase, nitric oxide, and cyclooxygenase-2 in splenocytes activated with T cell stimulants: role of interferon-gamma. Endocrinology. 2006;147(2):662–671.
   PubMed Web of Science ®Google Scholar
• Correale J, Arias M, Gilmore W. Steroid hormone regulation of cytokine secretion by proteolipid protein-specific CD4+ T cell clones isolated from multiple sclerosis patients and normal control subjects. J Immunol. 1998;161(7):3365–3374.
   PubMed Web of Science ®Google Scholar
• Marks MA, Gravitt PE, Burk RD, Studentsov Y, Farzadegan H, Klein SL. Progesterone and 17beta-estradiol enhance regulatory responses to human papillomavirus type 16 virus-like particles in peripheral blood mononuclear cells from healthy women. Clin Vaccine Immunol. 2010;17(4):609–617.
   Google Scholar
• Mjosberg J, Svensson J, Johansson E, et al. Systemic Reduction of Functionally Suppressive CD4dimCD25highFoxp3+ Tregs in Human Second Trimester Pregnancy Is Induced by Progesterone and 17beta- Estradiol. J Immunol. 2009;183(1):759–769.
   PubMed Web of Science ®Google Scholar
• Piccinni MP, Scaletti C, Maggi E, Romagnani S. Role of hormonecontrolled Th1- and Th2-type cytokines in successful pregnancy. J Neuroimmunol. 2000;109(1):30–33.
   PubMed Web of Science ®Google Scholar
• Kaushic C, Ashkar AA, Reid LA, Rosenthal KL. Progesterone increases susceptibility and decreases immune responses to genital herpes infection. J Virol. 2003;77(8):4558–4565.
   PubMed Web of Science ®Google Scholar
• Schiffman M, Kj aer SK. Chapter 2: Natural history of anogenital human papillomavirus infection and neoplasia. J Natl Cancer Inst Monogr. 2003(31):14–19.
   Google Scholar
• Richardson H, Abrahamowicz M, Tellier PP, et al. Modifiable risk factors associated with clearance of type-specific cervical human papillomavirus infections in a cohort of university students. Cancer Epidemiol Biomarkers Prev. 2005;14(5):1149–1156.
   Web of Science ®Google Scholar
• Sycuro LK, Xi LF, Hughes JP, et al. Persistence of genital human papillomavirus infection in a long-term follow-up study of female university students. J Infect Dis. 2008;198(7):971–978.
   PubMed Web of Science ®Google Scholar
• Shew ML, Fortenberry JD, Tu W, et al. Association of condom use, sexual behaviors, and sexually transmitted infections with the duration of genital human papillomavirus infection among adolescent women. Arch Pediatr Adolesc Med. 2006;160(2):151–156.
   Google Scholar
• Nielsen A, Kjaer SK, Munk C, Osler M, Iftner T. Persistence of highrisk human papillomavirus infection in a population-based cohort of Danish women. J Med Virol. 2010;82(4):616–623.
   PubMed Web of Science ®Google Scholar
• Munoz N, Hernandez-Suarez G, Mendez F, et al. Persistence of HPV infection and risk of high-grade cervical intraepithelial neoplasia in a cohort of Colombian women. Br J Cancer. 2009;100(7):1184–1190.
   Web of Science ®Google Scholar
• Molano M, Van den Brule A, Plummer M, et al. Determinants of clearance of human papillomavirus infections in Colombian women with normal cytology: a population-based, 5-year follow-up study. Am J Epidemiol. 2003;158(5):486–494.
   PubMed Web of Science ®Google Scholar
• Maucort-Boulch D, Plummer M, Castle PE, et al. Predictors of human papillomavirus persistence among women with equivocal or mildly abnormal cytology. Int J Cancer. 2010;126(3):684–691.
   PubMed Web of Science ®Google Scholar
• Chen YH, Huang LH, Chen TM. Differential effects of progestins and estrogens on long control regions of human papillomavirus types 16 and 18. Biochem Biophys Res Commun. 1996;224(3):651–659.
   Web of Science ®Google Scholar
• Mitrani-Rosenbaum S, Tsvieli R, Tur-Kaspa R. Oestrogen stimulates differential transcription of human papillomavirus type 16 in SiHa cervical carcinoma cells. J Gen Virol. 1989;70(Pt 8):2227–2232.
   Google Scholar
• Mittal R, Tsutsumi K, Pater A, Pater MM. Human papillomavirus type 16 expression in cervical keratinocytes: role of progesterone and glucocorticoid hormones. Obstet Gynecol. 1993;81(1):5–12.
   Web of Science ®Google Scholar
• Ruutu M, Wahlroos N, Syrjanen K, Johansson B, Syrjanen S. Effects of 17beta-estradiol and progesterone on transcription of human papillomavirus 16 E6/E7 oncogenes in CaSki and SiHa cell lines. Int J Gynecol Cancer. 2006;16(3):1261–1268.
   Web of Science ®Google Scholar
• Kim CJ, Um SJ, Kim TY, et al. Regulation of cell growth and HPV genes by exogenous estrogen in cervical cancer cells. Int J Gynecol Cancer. 2000;10(2):157–164.
   Web of Science ®Google Scholar
• Hwang JY, Lin BY, Tang FM, Yu WC. Tamoxifen stimulates human papillomavirus type 16 gene expression and cell proliferation in a cervical cancer cell line. Cancer Res. 1992;52(24):6848–6852.
   Web of Science ®Google Scholar
• Brake T, Lambert PF. Estrogen contributes to the onset, persistence, and malignant progression of cervical cancer in a human papillomavirus- transgenic mouse model. Proc Natl Acad Sci U S A. 2005;102(7):2490–2495.
   Web of Science ®Google Scholar
• Shai A, Brake T, Somoza C, Lambert PF. The human papillomavirus E6 oncogene dysregulates the cell cycle and contributes to cervical carcinogenesis through two independent activities. Cancer Res. 2007;67(4):1626–1635.
   Web of Science ®Google Scholar
• Arbeit JM, Howley PM, Hanahan D. Chronic estrogen-induced cervical and vaginal squamous carcinogenesis in human papillomavirus type 16 transgenic mice. Proc Natl Acad Sci U S A. 1996;93(7):2930–2935.
   Web of Science ®Google Scholar
• Chung SH, Lambert PF. Prevention and treatment of cervical cancer in mice using estrogen receptor antagonists. Proc Natl Acad Sci U S A. 2009;106(46):19467–19472.
   Web of Science ®Google Scholar
• Castle PE, Wacholder S, Lorincz AT, et al. A prospective study of high-grade cervical neoplasia risk among human papillomavirus- infected women. J Natl Cancer Inst. 2002;94(18):1406–1414.
   Google Scholar
• Castle PE, Walker JL, Schiffman M, Wheeler CM. Hormonal contraceptive use, pregnancy and parity, and the risk of cervical intraepithelial neoplasia 3 among oncogenic HPV DNA-positive women with equivocal or mildly abnormal cytology. Int J Cancer. 2005;117(6):1007–1012.
   Web of Science ®Google Scholar
• Moscicki AB, Ma Y, Wibbelsman C, et al. Rate of and risks for regression of cervical intraepithelial neoplasia 2 in adolescents and young women. Obstet Gynecol. 2010;116(6):1373–1380.
   PubMed Web of Science ®Google Scholar
• Deacon JM, Evans CD, Yule R, et al. Sexual behaviour and smoking as determinants of cervical HPV infection and of CIN3 among those infected: a case-control study nested within the Manchester cohort. Br J Cancer. 2000;83(11):1565–1572.
   Web of Science ®Google Scholar
• Munoz N, Bosch FX, de Sanjose S, et al. Risk factors for cervical intraepithelial neoplasia grade III/carcinoma in situ in Spain and Colombia. Cancer Epidemiol Biomarkers Prev. 1993;2(5):423–431.
   Web of Science ®Google Scholar
• Hildesheim A, Herrero R, Castle PE, et al. HPV co-factors related to the development of cervical cancer: results from a population-based study in Costa Rica. Br J Cancer. 2001;84(9):1219–1226.
   Web of Science ®Google Scholar
• Kjellberg L, Hallmans G, Ahren AM, et al. Smoking, diet, pregnancy and oral contraceptive use as risk factors for cervical intra-epithelial neoplasia in relation to human papillomavirus infection. Br J Cancer. 2000;82(7):1332–1338.
   PubMed Web of Science ®Google Scholar
• Trimble CL, Frazer IH. Development of therapeutic HPV vaccines. Lancet Oncol. 2009;10(10):975–980.
   Web of Science ®Google Scholar
• Chung SH, Franceschi S, Lambert PF. Estrogen and ERalpha: Culprits in cervical cancer? Trends Endocrinol Metab. 2010 Apr 22.
   Web of Science ®Google Scholar
• Castle PE. Do selective estrogen receptor modulators treat cervical precancer and cancer? Time to pool data from relevant trials. Int J Cancer. 2011;128(4):997–998.
   Web of Science ®Google Scholar
• Plummer M, Schiffman M, Castle PE, Maucort-Boulch D, Wheeler CM. A 2-year prospective study of human papillomavirus persistence among women with a cytological diagnosis of atypical squamous cells of undetermined significance or low-grade squamous intraepithelial lesion. J Infect Dis. 2007;195(11):1582–1589.
   PubMed Web of Science ®Google Scholar